<DOC>
	<DOC>NCT00704366</DOC>
	<brief_summary>This is a dose escalation study to assess the safety and tolerability of AZD0530 in patients with advanced solid malignancies.</brief_summary>
	<brief_title>AZD0530 Study 21 - Phase I Study in Patients With Solid Tumours</brief_title>
	<detailed_description />
	<mesh_term>Saracatinib</mesh_term>
	<criteria>Histologically or cytologically confirmed advanced carcinoma / solid tumour of known primary site, which is refractory to standard therapies or for which no standard therapy exists World Health Organisation (WHO) performance status 0 to 2 Life expectancy of at least 12 weeks Inadequate bone marrow reserve Inadequate liver function, renal function or low hemoglobin Unresolved toxicity from anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Advanced carcinoma</keyword>
</DOC>